[First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A].
The first botulinum toxin type B (BT-B) formulation, NeuroBloc, has been licensed in Germany for the treatment of cervical dystonia since March 2001. This allows the treatment of patients with secondary failure of botulinum type A (BT-A) injections for the first time. Three patients with such a secondary failure were successfully treated with BT-B. A total of 1,000 mouse units (MU) NeuroBloc per eye were injected in a patient with blepharospasm. The treatment was effective for 4 months. In a patient with spasmodic dysphonia, 250 MU were injected into each vocal cord. This was effective for 3.5 months. The third patient suffered from bilateral Frey's syndrome. A total of 7,500 MU were used on the right side and 6,000 MU on the left side to stop the gustatory sweating for 9 months. Overall, BT-B showed similar intervals of effectiveness as BT-A. Side effects were not seen using the above dosage regimes.
Guntinas-Lichius
O
O
Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Kopf- und Hals-Chirurgie, Universität zu Köln. orlando.guntinas@uni-koeln.de
D000368:Aged; D001764:Blepharospasm / Q000188:drug therapy*; D001905:Botulinum Toxins / Q000008:administration & dosage*; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D013547:Sweating, Gustatory / Q000188:drug therapy*; D017211:Treatment Failure; D014832:Voice Disorders / Q000188:drug therapy*
C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A